论文部分内容阅读
采用化疗治疗小细胞肺癌时中枢神经系统(CNS)衰竭发生率很高,应行预防性颅内放射(PCI)防止小细胞肺癌(SCLC)脑转移。SCLC 最易发生脑转移,Newan 和Hansen 发现33%～42%的SCLC 患者在死亡时CNS 受累,30%患者CNS 发生病变.Nagent 等报道用化疗维持生命2年的患者最后还是死亡,尸检中80%的患者CNS 转移,其中17%首发CNS 衰竭,并在大脑处有大量转移灶、脑转移后预计寿命为3.7～7个月。由于只有少量药物透过血脑屏障,化疗不能明显地减少脑转移的危
The incidence of central nervous system (CNS) failure when chemotherapy is used to treat small cell lung cancer is high. Prophylactic intracranial radiation (PCI) should be used to prevent small cell lung cancer (SCLC) brain metastases. SCLC is most likely to have brain metastases. Newan and Hansen found that 33% to 42% of SCLC patients had CNS involvement at the time of death, and 30% had CNS lesions. Nagent et al. reported that patients who had been on chemotherapy for 2 years were still dead. % of patients had CNS metastases, of which 17% had CNS failure and had a large number of metastases in the brain. Their estimated life expectancy after brain metastases was 3.7 to 7 months. Chemotherapy does not significantly reduce the risk of brain metastases because only a small amount of drugs cross the blood-brain barrier